Clinical Trial Update: 2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (sponsored by European LeukemiaNet) is evaluating stopping nilotinib after two years in chronic myeloid leukemia patients; the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: European LeukemiaNet | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING